TABLE 1.
CircRNAs are involved in the development of AS risk factors.
Risk factor | CircRNA | Dysregulation | Function | Cell/Model | Ref |
---|---|---|---|---|---|
Dyslipedemia | CircRNA_0046367 | Down | Prevent hepatoxicity of lipid peroxidation against hepatic steatosis | HepG2 cells | Guo et al. (2017a) |
CircRNA_0046366 | Down | Facilitate the transcriptional activation of lipid metabolism-associated genes | HepG2 cells | Guo et al. (2018) | |
CircRNA_021412 | Down | Disturb the balance between catalytic separation and adipogenesis | HepG2 cells | Guo et al. (2017b) | |
CircScd1 | Down | Impede lipid droplet formation and triglyceride content | AML-12 cells | Li et al. (2019a) | |
Circ_0057558 | Up | Facillitate lipogenesis and TG secretion | Huh-7 and HepG2 cells | Chen et al. (2021) | |
CircACC1 | Up | Facilitate the stability and activity of AMPK | HCT116 and LO2 cells | Li et al. (2019b) | |
CDR1AS | Down | Increase insulin content and secretion | MIN6 cells | Xu et al. (2015) | |
Diabetes | CircHIPK3 | Down | Impair the proliferation and capacity of insulin secretion and survival | Human islets cells | Cao et al. (2018) |
CircWDR77 | Up | Promote high glucose induced proliferation and migration | Human VSMCs | Chen et al. (2017) | |
Circ_0068087 | Up | Promote chronic inflammation and vascular EC dysfunction in HG condition | HUVECs | Cheng et al. (2019) | |
CircANKRd36 | Up | Promote inflammation and cell apoptosis in the pancreatic tissues | T2DM rat model | Fang et al. (2018a) | |
CircPPM1F | Up | promote activation and facilitate injury in pancreatic islets | PBMCs | Zhang et al. (2020a) | |
Hsa_circH19 | Up | Alleviate adipogenic differentiation | Human ADSCs | Zhu et al. (2020a) | |
Obesity | CircARF3 | Up | Alleviate mitophagy-mediated inflammation and adipose inflammation | preadipocyte | Zhang et al. (2019a) |
CircSAMD4A | Up | Promote the differentiation of preadipocytes and obesity | preadipocyte | Liu et al. (2020) | |
CircNrxn2 | Down | Alleviate e WAT browning | preadipocyte | Zhang et al. (2019b) | |
CiRS-133 | Up | Promote WAT browning | preadipocyte | Zhang et al. (2019c) | |
Has_circ_0126991 | Up | Unknown | — | Liu et al. (2019a) | |
Hypertension | Has_circ_0005870 | Down | Unknown | — | Wu et al. (2017) |
Has_circ_0037911 | Up | Chang the concentration of Scr | — | Bao et al. (2018) | |
CircZNF609 | Up | Inhibit endothelial cell migration, tube formation, and apoptosis | HUVECs | Liu et al. (2017) | |
Has_circ_0014243 | Up | Unknown | — | Zheng et al. (2019) | |
Hsa_circ_0105015 | Up | Inflammatory pathways | HUVECs | He et al. (2021) | |
Hsa_circ_0039388 | Up | Enhance viability and invasive properties | HASMCs | Yin et al. (2020) | |
Hsa_circ_0038648 | Up | Enhance viability and invasive properties | HASMCs | Yin et al. (2020) | |
Has-circRNA9102-5 | Up | Unknown | — | Zheng et al. (2020) | |
CircNr1h4 | Down | Involved in hypertensive kidney injury | Mouse kidney collecting duct cells | Lu et al. (2020) | |
Hsa_circ_0037897 | Up | Unknown | — | Tao et al. (2021) |
TG, total cholesterol; AMPK, AMP-activated protein kinase; EC, endothelial cell; HG, high glucose; WAT, white adipose tissue; Scr, serum creatinine; VSMCs, vascular smooth muscle cells; T2DM, type 2 diabetes mellitus; PBMCs, peripheral blood mononuclear cells; ADSCs, adipose-derived stem cells; HUVECs, human vein endothelial cells; HASMCs, human aortic endothelial cells.